Thus, MOGAD is generally considered to have a favorable prognosis compared to other CNS demyelinating diseases such as AQP-4 positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). This evidence concerns the gene AQP4 and multiple sclerosis.